Trials / Completed
CompletedNCT00827190
Study Evaluating Single Ascending Doses Of ILS-920
Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of ILS-920 Administered Intravenously To Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This is a first-in-human study of ILS-920. This study will provide an initial assessment of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ILS-920 after administration of ascending single intravenous (IV) doses to healthy adult subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ILS-920 |
Timeline
- Start date
- 2009-02-01
- Primary completion
- 2009-07-01
- Completion
- 2009-07-01
- First posted
- 2009-01-22
- Last updated
- 2010-02-03
Source: ClinicalTrials.gov record NCT00827190. Inclusion in this directory is not an endorsement.